Aldeyra Therapeutics (ALDX) Consolidated Net Income (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Consolidated Net Income of -$3.5 million for Q1 2026, up 47.88% on a QoQ basis from -$6.6 million in Q4 2025, and up 80.38% year-over-year from -$1.9 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Consolidated Net Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$3.5 million for Q1 2026.
- Quarterly Consolidated Net Income rose 80.38% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 52.11% YoY) and the FY2025 annual result came in at -$38.5 million, up 34.45% from the prior year.
- Consolidated Net Income was -$3.5 million for Q1 2026 at Aldeyra Therapeutics, up from -$6.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$3.5 million in Q1 2026 and bottomed at -$41.5 million in Q1 2023.
- A 5-year average of -$16.0 million and a median of -$15.8 million in 2024 frame the typical range for Consolidated Net Income.
- Peak annual rise in Consolidated Net Income reached 80.52% in 2024, while the deepest fall reached 212.27% in 2024.
- Aldeyra Therapeutics' Consolidated Net Income stood at -$13.2 million in 2022, then surged by 61.62% to -$5.0 million in 2023, then slumped by 212.27% to -$15.8 million in 2024, then surged by 57.97% to -$6.6 million in 2025, then soared by 47.88% to -$3.5 million in 2026.
- Business Quant data shows ALDX's Consolidated Net Income at -$3.5 million in Q1 2026, -$6.6 million in Q4 2025, and -$14.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.62 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -15.76 Mn |
| Sep 30, 2024 | -22.02 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -25.96 Mn |
| Mar 31, 2023 | -41.50 Mn |
| Dec 31, 2022 | -13.15 Mn |
| Sep 30, 2022 | -19.03 Mn |
| Jun 30, 2022 | -18.97 Mn |
| Mar 31, 2022 | -18.58 Mn |
| Dec 31, 2021 | -16.07 Mn |
| Sep 30, 2021 | -27.38 Mn |
| Jun 30, 2021 | -35.84 Mn |